miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0317385 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Yi Cen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Imaging, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China. Hauptthemen laut MEDLINE: MicroRNAs, Prostatic Neoplasms, Prostate-Specific Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Plan on enhancing scientific research in GMU.
Abstract (Originalsprache)
Background
Prostate-specific antigen (PSA) is commonly used as a biomarker to diagnose and predict the course of prostate cancer (PCa). However, PSA detection is susceptible to changes in the physiologic environment, which may lead to some misdiagnosis. Thus, it is crucial to find a novel diagnostic marker.
Methods
We accessed microRNA (miRNA) expression datasets (GSE206793 and GSE112264) from the GEO database, analyzing peripheral blood samples from PCa patients. Differentially expressed miRNAs (DEmiRNAs) were identified using GEO2R. A specific miRNA, miR-455-3p, was pinpointed through rigorous analysis of clinical correlations and ROC curves. Peripheral blood samples from healthy individuals and PCa patients were subjected to qRT-PCR validation, aligning results with the GSE206793 dataset. The miRWalk database was utilized to predict downstream genes, while STRING facilitated the construction of a protein-protein interaction (PPI) network. KEGG pathway analysis enriched our understanding of potential molecular pathways.
Results
We found that miR-455-3p was highly expressed in the peripheral blood of PCa patients with Gleason score (GS) ≥ 8, while independent of T stage, age and PSA. ROC analysis revealed a favorable diagnostic efficacy of miR-455-3p and AUC for the two datasets was respectively 0.943 and 0.847. The qRT-PCR assay also revealed consistent results. Interestingly, the PSA levels of P1 (GS = 5 + 4) and P6 (GS = 3 + 3) were respectively 3.38 and 4.45 ng/ml, while miR-455-3p was highly expressed in both, suggesting its low misdiagnosis. The speculation was validated in GSE206793 dataset. Finally, 9 potential targets of miR-455-3p were predicted. PPI network revealed PPP2R2A, ITGB1 and CDKN1A as key nodes. KEGG pathway analysis revealed that they were enriched in various cancers, biological processes and molecular signals.
Conclusion
Our study identifies miR-455-3p as a promising diagnostic marker for PCa, outperforming PSA in terms of specificity and sensitivity. The robustness of miR-455-3p, coupled with its potential downstream targets and associated pathways, highlights its clinical significance for improved PCa diagnosis and management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Imaging, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, P. R. China.
- Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, P. R. China.
- State Key Laboratory of Biocontrol, School of Life Sciences, Sun Yat-sen University, Guangzhou, P. R. China.
- Department of Thyroid and Breast Surgery, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, P. R. China.
- Department of Urology, Second Affiliated Hospital of Bengbu Medical College, Bengbu, P. R. China.
- Shenzhen Bao'an Chinese Medicine Hospital,Guangzhou University of Chinese Medicine, Shenzhen, P. R. China.
ORCID-Profile: Guangbin Zhu
Förderung
- National Natural Science Foundation of China
- Plan on enhancing scientific research in GMU
Zitieren
APA
Cen, Y., Feng, S., Xu, Y., Zhang, C., Lin, X., Ye, X., Zha, Z., Wang, H., & Zhu, G. (2025). miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer. PLOS ONE. https://doi.org/10.1371/journal.pone.0317385
Vancouver
Cen Y, Feng S, Xu Y, Zhang C, Lin X, Ye X, et al. miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer. PLOS ONE. 2025. doi:10.1371/journal.pone.0317385
BibTeX
@article{Cen2025,
author = {Cen, Yi and Feng, Shourui and Xu, Yuyu and Zhang, Churuo and Lin, Xiangjin and Ye, Xuan and Zha, Zeyu and Wang, Haiyan and Zhu, Guangbin},
title = {miR-455-3p has superior diagnostic potential to PSA in peripheral blood for prostate cancer},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0317385}
}
EUVIMED